These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial. Kashiwagi S; Watanabe A; Ikematsu H; Awamura S; Okamoto T; Uemori M; Ishida K J Infect Chemother; 2013 Aug; 19(4):740-9. PubMed ID: 23732307 [TBL] [Abstract][Full Text] [Related]
3. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Sugaya N; Ohashi Y Antimicrob Agents Chemother; 2010 Jun; 54(6):2575-82. PubMed ID: 20368393 [TBL] [Abstract][Full Text] [Related]
4. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Wang K; Shun-Shin M; Gill P; Perera R; Harnden A Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD002744. PubMed ID: 22513907 [TBL] [Abstract][Full Text] [Related]
5. Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects. Toyama K; Furuie H; Ishizuka H Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061751 [TBL] [Abstract][Full Text] [Related]
6. Inhaled Laninamivir Octanoate as Prophylaxis for Influenza in Children. Nakano T; Ishiwada N; Sumitani T; Uemori M; Isobe K; Pediatrics; 2016 Dec; 138(6):. PubMed ID: 27940664 [TBL] [Abstract][Full Text] [Related]
7. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Ikematsu H; Kawai N Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296 [TBL] [Abstract][Full Text] [Related]
8. Neuraminidase inhibitors for preventing and treating influenza in children. Wang K; Shun-Shin M; Gill P; Perera R; Harnden A Cochrane Database Syst Rev; 2012 Jan; 1():CD002744. PubMed ID: 22258949 [TBL] [Abstract][Full Text] [Related]
9. Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers. Ishizuka H; Toyama K; Yoshiba S; Okabe H; Furuie H Antimicrob Agents Chemother; 2012 Jul; 56(7):3873-8. PubMed ID: 22526307 [TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza. Higashiguchi M; Matsumoto T; Fujii T Antivir Ther; 2018; 23(2):157-165. PubMed ID: 28869418 [TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection. Yoshihara K; Ishizuka H; Kubo Y Drug Metab Pharmacokinet; 2013; 28(5):416-26. PubMed ID: 23574886 [TBL] [Abstract][Full Text] [Related]
12. A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases. Watanabe A J Infect Chemother; 2013 Feb; 19(1):89-97. PubMed ID: 22907567 [TBL] [Abstract][Full Text] [Related]
13. Drug-induced pneumonitis following the administration of laninamivir octanoate: The first two reported cases. Ogawa T; Tanaka K; Ohgino K; Omori N; Betsuyaku T; Sayama K J Infect Chemother; 2019 Dec; 25(12):1043-1046. PubMed ID: 31178281 [TBL] [Abstract][Full Text] [Related]
14. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Watanabe A; Chang SC; Kim MJ; Chu DW; Ohashi Y; Clin Infect Dis; 2010 Nov; 51(10):1167-75. PubMed ID: 20936975 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season. Koseki N; Kaiho M; Kikuta H; Oba K; Togashi T; Ariga T; Ishiguro N Influenza Other Respir Viruses; 2014 Mar; 8(2):151-8. PubMed ID: 23953886 [TBL] [Abstract][Full Text] [Related]
16. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. Vavricka CJ; Li Q; Wu Y; Qi J; Wang M; Liu Y; Gao F; Liu J; Feng E; He J; Wang J; Liu H; Jiang H; Gao GF PLoS Pathog; 2011 Oct; 7(10):e1002249. PubMed ID: 22028647 [TBL] [Abstract][Full Text] [Related]
17. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate; comparison of the 2011/12 to 2015/16 Japanese influenza seasons. Ikematsu H; Kawai N; Iwaki N; Kashiwagi S J Infect Chemother; 2017 Sep; 23(9):627-633. PubMed ID: 28709902 [TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance. Kashiwagi S; Yoshida S; Yamaguchi H; Mitsui N; Tanigawa M; Shiosakai K; Yamanouchi N; Shiozawa T; Yamaguchi F J Infect Chemother; 2013 Apr; 19(2):223-32. PubMed ID: 23085742 [TBL] [Abstract][Full Text] [Related]
19. Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection. Mizuno T; Mizuno S; Kanda T PLoS One; 2014; 9(4):e92601. PubMed ID: 24699254 [TBL] [Abstract][Full Text] [Related]
20. Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics. Sunagawa S; Higa F; Cash HL; Tateyama M; Uno T; Fujita J Influenza Other Respir Viruses; 2013 Jan; 7(1):1-3. PubMed ID: 22405585 [No Abstract] [Full Text] [Related] [Next] [New Search]